key: cord-0922348-iaq0g3e4 authors: Li, Yanbai; Wang, Lili; Si, Helong; Yu, Zhengsen; Tian, Shijun; Xiang, Rong; Deng, Xiaoqian; Liang, Ruiying; Jiang, Shibo; Yu, Fei title: Influenza Virus Glycoprotein-reactive Human Monoclonal Antibodies date: 2020-06-19 journal: Microbes Infect DOI: 10.1016/j.micinf.2020.06.003 sha: 07d5f4680646ff38b1816403bad1a05cff176036 doc_id: 922348 cord_uid: iaq0g3e4 Influenza continues to be a significant public health challenge. Two glycoproteins on the surface of influenza virus, hemagglutinin and neuraminidase, play a prominent role in the process of influenza virus infection and release. Monoclonal antibodies targeting glycoproteins can effectively prevent the spread of the virus. In this review, we summarized currently reported human mAbs targeting glycoproteins of influenza A and B viruses. Mouse-derived mAbs are simple to prepare and relatively inexpensive, but they can induce 87 immunity in the body, and they are difficult to apply clinically. On the contrary, human mAbs 88 can substantially reduce immune side effects caused by heterogeneous antibodies to the 89 human body, and this is a future research direction of influenza antibody drugs [27] . 90 Therefore, we herein review human mAbs targeting HA and NA, focusing on their broad 91 antiviral spectrum and mechanisms of action. crystal structure indicates that the binding site of M826 is completely exposed when the 153 conformation of HA trimer is changed by pH induction. This is a unique epitope that exists in [67] . The results showed that VIS410 is generally safe, has potential to reduce the incidence 261 of disease, can greatly reduce hospitalization rates for people over age 65, and can be 262 recommended as a drug for the treatment or prevention of IAVs [67] . Recently, the safety and In summary, application of mAbs isolated from humans capable of neutralizing a variety of 319 IAV and IBV subtypes is the most effective way to prevent and treat influenza and is a major 320 direction for future research. However, because of HA and NA antigenic drift, treatment with 321 mAbs often cannot achieve the desired effect. This calls for the further exploration of HA and 322 NA conserved sites and mechanisms of action. The authors declare that they have no conflicts of interest. Influenza B virus evolution: co-circulating lineages and 356 comparison of evolutionary pattern with those of influenza A and C viruses The structure and function of the hemagglutinin membrane glycoprotein of influenza 358 virus Heterosubtypic antibody recognition of the 360 influenza virus hemagglutinin receptor binding site enhanced by avidity Natural and directed antigenic drift 363 of the H1 influenza virus hemagglutinin stalk domain Structure of the influenza virus 365 haemagglutinin complexed with its receptor, sialic acid Neuraminidase is important for the 367 initiation of influenza virus infection in human airway epithelium Combination therapy with anti-HIV-1 369 antibodies maintains viral suppression A single injection of anti-HIV-1 371 antibodies protects against repeated SHIV challenges SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E 374 viral proteins A humanized neutralizing antibody against MERS-CoV targeting 376 the receptor-binding domain of the spike protein Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead Anti-Ebola therapy for patients 381 with Ebola virus disease: a systematic review Hendra virus and Nipah virus animal vaccines Tackling influenza with broadly 384 neutralizing antibodies Protective 386 antibodies against influenza proteins Universal influenza virus vaccines and therapeutic antibodies Human monoclonal antibodies: The benefits of humanization antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin Viral receptor-binding site 402 antibodies with diverse germline origins Naturally occurring antibodies in 404 humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5 modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity Structural basis of tyrosine sulfation 446 and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120 Antibody 27F3 broadly targets influenza A group 1 and 2 449 hemagglutinins through a further variation in VH1-69 antibody orientation on the HA stem Heterosubtypic 452 neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ 453 memory B cells Antibody recognition of a 455 highly conserved influenza virus epitope A highly conserved neutralizing 457 epitope on group 2 influenza A viruses A common solution to group 2 459 influenza virus neutralization Structural and functional bases for 461 broad-spectrum neutralization of avian and human influenza A viruses A neutralizing antibody selected from 464 plasma cells that binds to group 1 and group 2 influenza A hemagglutinins Pandemic H1N1 influenza vaccine 466 induces a recall response in humans that favors broadly cross-reactive memory B cells An in vivo human-plasmablast enrichment 469 technique allows rapid identification of therapeutic influenza A antibodies Phase 2 randomized trial of the safety and 471 efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge 472 model Two phase 1, randomized, double-blind, 474 placebo-controlled, single-ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of 475 an anti-influenza A virus monoclonal antibody, MHAA4549A, in healthy volunteers Human monoclonal antibody 81.39a 478 effectively neutralizes emerging influenza A viruses of group 1 and 2 hemagglutinins Alternative recognition of the conserved 480 stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody A potent broad-spectrum protective human 483 monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus A broadly neutralizing 486 human monoclonal antibody is effective against H7N9 Safety and upper 488 respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and 489 prophylaxis based on population modeling of seasonal influenza A outbreaks Safety and efficacy of monoclonal 491 antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, 492 phase-2, placebo-controlled study Structure and function analysis of 494 an antibody recognizing all influenza A subtypes Rapid development of broadly 496 influenza neutralizing antibodies through redundant mutations The hemagglutinin A stem 498 antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. The 499 A phase 1 study to evaluate the safety and 501 pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers Evaluation of MEDI8852, an 504 anti-influenza A monoclonal antibody, in treating acute uncomplicated influenza Influenza infection in humans induces 507 broadly cross-reactive and protective neuraminidase-reactive antibodies Hemagglutinin stalk-reactive antibodies interfere with 509 influenza virus neuraminidase activity by steric hindrance Discordant antigenic drift of 511 neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses Broad and protective influenza 514 B virus neuraminidase antibodies in humans after vaccination and their clonal persistence as plasma cells Human antibodies 517 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses Efficacy and safety of 520 treatment with an anti-m2e monoclonal antibody in experimental human influenza